Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

11 Jun 2024 09:00 CEST

Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-
Health Group Technology Co. Ltd (Lithy) as an additional distributor in China.

Shanghai-based Lithy has entered into an agreement with HBC to distribute its
science-led marine nutrition ingredients, ProGo® bioactive peptides, OmeGo® full
spectrum omegas and CalGo® natural, undenatured type II collagen, to supplement
manufacturers across the country.

Lithy, which was established in 2002, has three subsidiaries that supply
botanical extracts and dietary supplement ingredients to the Chinese
nutraceutical and pharmaceutical markets. Lithy also has in-house manufacturing
capabilities and a number of ready-to-go formulations using HBC ingredients.

James Berger, Chief Commercial Officer for HBC, said: "We are excited to take
this important step in our partnership with Lithy, to establish the additional
distribution in China of our science-led marine nutrition ingredients and
further develop product formulations that are ready-to-go to market via brand
owners."

HBC is a Norwegian consumer and pet health company that specialises in science-
led marine nutrition. The company is founded on the core values of
sustainability, traceability and optimal utilization of natural resources.

For more information about Hofseth BioCare, visit: hofsethbiocare.com

About HBC:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. For OmeGo, clinical trial work with our
salmon oil is ongoing to improve lung health in allergic asthma and urban
populations with exposure to raised pollution levels. A study in mild COVID has
completed successfully demonstrating important immune health benefits for faster
recovery. For CalGo, preclinical and clinical trial work is delineating the
joint health benefits of the natural, undenatured type II collagen contained in
it. ProGo provides both metabolic and gastrointestinal (GI) health benefits. The
former includes GLP1 activity and hence consistent weight loss with improved
energy levels from improved iron metabolism. The peptides also support muscle
health providing a triad of benefits important for healthy ageing and active
lifestyles. In terms of GI health, a special formula of soluble protein
hydrolysate (SPH / ProGo®) is being developed as a Medical Food to help treat
Inflammatory Bowel Disease, and for Iron Deficiency Anemia. Research is ongoing
to identify the individual elements within its ingredients that modulate
inflammation and the immune response with pre-clinical studies ongoing in
multiple clinics and University research labs.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, New Jersey and Palo Alto. HBC is listed on
Oslo Børs with ticker "HBC".

For further information on HBC, please contact:??

Nick Frampton (PhD), Global Head of Consumer Health at HBC
nick@hofsethbiocare.com
??
For press information or to arrange an interview, please contact:??
Sara Houghton, BDB??
hofsethbiocare@bdb.co.uk ??
(+44) 161 925 4700

More information:
Access the news on Oslo Bors NewsWeb site